Lates News

According to Every AI, Pacific Securities released a research report on September 7, giving a buy rating to Xinmiao Medical (688016.SH). The main reasons for the rating include: 1) Research and development results are gradually being realized, with sufficient reserves of growth momentum in the future; 2) Going abroad is advancing rapidly, with revenue in the first half of the year nearly doubling year-on-year; 3) Gross profit level is affected by product price reductions, while expenses are rising. (Daily Economic News)